Gossamer Bio vs Gyre Therapeutics
GOSS and GYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GOSS and GYRE compare
Gossamer Bio is the larger company, worth 11 times as much as Gyre Therapeutics ($5.4B against $508M).
Gossamer Bio grew revenue faster over the last twelve months (32.4% versus −3.7% for Gyre Therapeutics).
Gyre Therapeutics keeps more of each dollar of sales as profit, with a net margin of −33.9% compared with −235% at Gossamer Bio.
Gyre Therapeutics scores higher on the StockData Score (11 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GOSS | GYRE |
|---|---|---|
| Size and price | ||
| Market cap | $5.4B | $508M |
| Share price | $11.04 | $4.56 |
| Change, 1 year | −94.9% | −42.9% |
| Change, 5 years | −98.7% | −75.7% |
| Beta (5Y) | 2.33 | 1.21 |
| Employees | 161 | 618 |
| StockData Score | ||
| Total score | 1 | 11 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 0 | 3 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 101× | 4.7× (better) |
| P/B | – | 4.7× |
| FCF yield | −3.0% | −1.5% (better) |
| Fair value | – | $5.29 |
| Margin of safety | – | 13.8% |
| Growth | ||
| Revenue growth (TTM) | 32.4% (better) | −3.7% |
| Revenue growth, 5Y average | – | 41.0% |
| Net income growth (TTM) | – | −801% |
| Profitability | ||
| Gross margin | – | 93.4% |
| Operating margin | −312% | −14.4% (better) |
| Net margin | −235% | −33.9% (better) |
| FCF margin | −305% | −7.2% (better) |
| Return on equity | – | −34.9% |
| Return on invested capital | – | −26.6% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −15.2× | – |
| Current ratio | 0.53 | 4.32 (better) |
| Altman Z-score | −15.26 | 8.53 (better) |
| Piotroski F-score | 1 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.98% | 7.8% |
| Held by insiders | 2.8% | 93.8% |
| Insider net buying, 12 months | – | −$953K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 0.28% | 32.4% |
Go deeper
- GOSS stock overview
- GOSS income statement
- GOSS valuation and score
- GYRE stock overview
- GYRE income statement
- GYRE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.